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Objective: To understand current genetic counseling and testing practices for late-onset 
neurodegenerative diseases (LONDs), and identify whether practices address the goals of 
genetic counseling. 
Methods: We performed a literature search using CINAHL, MEDLINE, PsycINFO, and 
EMBASE, for articles published from 2009 to 2020. Any peer-reviewed research articles in 
English that reported research and clinical genetic counseling and testing practices for 
LONDs were included. We used narrative synthesis to describe different practices and map 
genetic counseling activities to the goals of genetic counseling: interpretation, counseling, 
education, and support. Risk of bias was assessed using the Qualsyst tool. The protocol was 
registered with PROSPERO (CRD42019121421). 
Results: Sixty-one studies sourced from 68 papers were included. Most papers focused on 
predictive testing (58/68) and Huntington’s disease (41/68). There was variation between 
papers in study design, study population, outcomes, interventions, and settings. Although 
there were commonalities, novel or inconsistent genetic counseling practices were identified. 
Eighteen papers addressed all four goals of genetic counseling. 
Conclusion: Current practices are varied and informed by local laws and protocols, resources, 
and the availability of different health providers. There was an emerging focus on flexible, 
multidisciplinary, client- and family-centered care. As genetic testing becomes a routine part 
of care for patients with LONDs (and their relatives), health providers must balance their 
limited time and resources with ensuring that clients are safely and effectively counseled. 
Areas of further research include diagnostic and reproductive genetic counseling/testing 
practices, evaluations of novel approaches to care, and the role and use of different health 




Late-onset neurodegenerative diseases (LONDs) highlight the complexities and challenges of 
genetic and genomic testing for patients and relatives 1, 2. Genetic counseling facilitates and 
supports individuals through the process of decision-making about testing 1, 2. Genetic 
counselors are allied health providers trained to provide this specialized care, however, the 
international shortage of genetic counselors requires other health providers to assume the role 
3. Health providers from outside of genetics are often unprepared to integrate genetic and 
genomic health information into routine clinical care due to a lack of resources and 
guidelines, low confidence in initiating genetics discussions, and concerns about 
discrimination and psychological harm 4. Examining current genetic counseling practices for 
individuals undergoing diagnostic, predictive, and reproductive testing for LONDs is 
therefore important to understand whether these practices adequately address genetic 
counseling goals. 
Genetic counseling is a communication process that aims to help individuals understand and 
adapt to the medical, psychological, familial, and reproductive implications of the genetic 
contribution to specific health conditions 5-7. Adequate knowledge and time allocated to 
provide genetic counseling is vital to maximize the health benefits of genetic testing while 
minimising harm to the client and their relatives 1, 2, 8. According to the Human Genetics 
Society of Australasia and the United States of America (USA)’s National Society of Genetic 
Counselors, the activities of genetic counseling should integrate the following four goals: 
1. Interpretation of family and medical histories to assess the chance of disease 
occurrence or recurrence 5, 6. 
2. Education about the natural history of the condition, inheritance pattern, testing, 
management, prevention, support resources, and research 5, 6. 
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3. Counseling to promote informed choices in view of risk assessment, family goals, 
ethical and religious values 5-7. 
4. Support to encourage the best possible adjustment to the disorder in an affected 
family member and/or to the risk of recurrence of that disorder 5, 7. 
Genetic counseling for different LONDs may be similar given their shared genetic and 
phenotypic characteristics as progressive diseases that can affect movement, cognition, 
behavior, personality, or communication, with few treatment or preventative options 
available to stop or slow progression 9, 10. Genetic testing, through next-generation 
sequencing, allows multiple LOND genes to be screened concurrently at lower cost and 
greater speed, and is becoming more common in neurology clinics 1, 11. There are three main 
categories of genetic testing available for LONDs: diagnostic, predictive, and reproductive 
testing. When a pathogenic variant (mutation) is identified in an affected patient through 
diagnostic testing, predictive or reproductive testing becomes available to biological relatives. 
Predictive (or pre-symptomatic) testing identifies whether an asymptomatic relative has 
inherited a pathogenic variant, which implies a future risk of disease (hereafter described as 
predictive testing). Reproductive testing provides the option to prevent inheritance of a 
pathogenic variant through testing a pregnancy (prenatal diagnosis) or in vitro fertilisation 
(IVF, pre-implantation genetic diagnosis). Individuals who do not wish to know their status 
as a pathogenic variant carrier may be able to undergo reproductive testing through exclusion 
or non-disclosure testing 12.  
Guidelines and protocols for genetic testing have been developed for a range of LONDs 13-19 
and are informed by the HD predictive and reproductive testing guidelines 13, 14, 20, 21. 
However, guidelines are not always translated into practice 22, 23. The primary aim of this 
review was to establish a comprehensive understanding of the evidence for current genetic 
counseling and testing practices for LONDs. The secondary aim was to identify to what 
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extent current practices address the established goals of genetic counseling. The findings will 
inform the development of a genetic counseling and testing model of service delivery for 
LONDs. 
METHODS 
Protocol and registration 
The systematic review protocol was registered on 01/20/2019 with the International 
Prospective Register of Systematic Reviews (PROSPERO, CRD42019121421) and was 
guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) Statement 24. 
Eligibility criteria 
The inclusion and exclusion criteria are listed in Table 1 and were developed using the 
PICOS framework 24. We wished to find commonalities in genetic counseling practices for 
different LONDs. Therefore, condition-specific aspects of genetic testing, such as 
anticipation in triplet repeat disorders, were not considered. Although the goal of genetic 
counseling is not necessarily to promote undergoing testing, we elected to refer to genetic 
counseling that involved situations where a genetic test is available. We included articles 
published since 2009 as we expected this would include current practices used since the 
advent of next-generation sequencing technology 11. 
Literature search strategy 
We searched four electronic databases (CINAHL, MEDLINE, PsycINFO, and EMBASE) 
with terms related to the target disease group and intervention (Table 2). Searches were 
combined and de-duplicated using Endnote X9. Further references were elicited through 
backward-searching the reference lists of included papers, and forward-searching using the 




The primary (AC) and secondary reviewer (ROS) piloted the inclusion criteria. AC then 
screened all references against the criteria at the title and abstract and full-text screening 
stage, and ROS independently assessed 10% of titles and abstracts and 20% of full texts. 
After each stage, disagreements were resolved through discussion. Where no agreement was 
reached, the decision to include or exclude was made by a third reviewer (AM). Inter-rater 
reliability after title and abstract and full-text screening, respectively, demonstrated a level of 
agreement of 96.8% and 91.5%, and at least strong agreement using the prevalence-adjusted 
bias-adjusted kappa (PABAK=0.94 and 0.83) 25, 26. The study selection process and reasons 
for exclusion are summarized in Figure 1. 
Data extraction and quality assessment 
AC completed data extraction and critical appraisal forms for each included paper, then ROS 
checked, verified, and validated these. Data items were related to the research question (e.g. 
genetic testing type, health provider role and involvement, number of appointments, 
requirement of a support person, and activities involved). The activities involved in genetic 
counseling practice were extracted, grouped in key topic areas, and mapped against the four 
goals of genetic counseling 5-7.  
The Qualsyst tool 27 was used to critically appraise the quality of included studies, as it 
allows for assessment of quantitative and qualitative research across a broad range of study 
designs, and has previously been used in genetic counseling and testing research 28-30. 
Narrative synthesis 
A systematic narrative synthesis was performed to describe variation between practices and 
activities 31. Narrative synthesis is a textual approach to synthesis and relies on the use of 
words and text to summarize and explain findings 31. A meta-analysis was not possible due to 
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the heterogeneity of included studies. No papers were excluded based on a quality threshold, 
but the methodological quality and potential biases between and within studies were assessed.  
Data availability statement 
Complete searches, data extraction tables and references are available in the supplemental 
data.  
RESULTS 
Study characteristics and quality appraisal 
Sixty-eight papers representing 61 studies were included (Table 3, further details in Table e-
2). Several studies focused on more than one condition or testing type. The most commonly 
studied condition was Huntington’s disease (HD) (41/68), followed by spinocerebellar 
ataxias (SCAs) (12/68) and amyotrophic lateral sclerosis (ALS)/frontotemporal dementia 
(FTD) (11/68). The majority of papers focused on predictive testing (58/68). Fewer papers 
focused on diagnostic (17/68) or reproductive (11/68) testing. Only 4/68 focused just on 
diagnostic testing, and 5/68 papers focused just on reproductive testing. Genetic counseling 
practices were reported from studies of clinical experience (32/68), novel practices trialed in 
clinical settings (6/68), and recommendations for practice from research (30/68).  
Twenty-four papers reported qualitative methods. Thirteen included papers used two different 
study types: qualitative and quantitative methods (8/13) or a combination of cohort study, 
case series, or case study (5/13). There were no randomized control trials. The total number 
of included participants is not easily comparable between studies given the variability in 
study design, study population, outcomes, interventions, and settings. Sixty papers (60/68) 




Narrative synthesis: genetic counseling practices for LONDs 
Genetic counseling and testing practices varied between the health providers involved and the 
requirement for a neurological or psychiatric/psychological assessment. The requirement for 
a support person and the minimum number of appointments before and after testing also 
varied. Thirty-nine papers reported specifically on at least one of these aspects (Table 4) and 
included 6/39 on diagnostic testing, 35/39 on predictive testing, and 5/39 on reproductive 
testing. 
Findings from the narrative synthesis are further summarized under the following topics 
related to understanding current genetic counseling and testing practices for LONDS and the 
extent they address the established goals of genetic counseling: the involvement and role of 
health providers, the number of appointments, the requirement of a support person, barriers to 
accessing genetic counseling and testing, the activities involved in genetic counseling 
practice, and addressing the goals of genetic counseling. Due to the limited available papers 
on diagnostic and reproductive testing, the focus is on predictive testing. However, diagnostic 
and reproductive testing practices are reported where available.  
(i) The involvement and role of health providers 
A multidisciplinary team of two or more health providers were involved in the genetic 
counseling practice in 33 papers (Table 4). The specific role of each health provider within 
the team was not always clearly described and varied between practices. Twenty-nine papers 
mentioned the role of neurologists, psychiatrists, and psychologists in assessing symptoms of 
disease or risk factors for coping. In some practices, clients were required to complete 
structured psychological or psychosocial surveys e5, e8, e11, e13, e15, e20, e33, e36, e44, e45, e49, or 
disease-specific neurological or objective knowledge measurement tools e8, e10 in addition to, 
or instead of a formal neurological or psychiatric/psychological assessment. In diagnostic and 
reproductive testing, neurological assessments were described once each e29, e37, and 
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psychological assessments were described in reproductive testing only e37. In reproductive 
testing, these assessments were performed if an individual was symptomatic at the time of 
reproductive testing discussions e37.  
Where symptoms were identified as part of the neurological or psychiatric/psychological 
assessment, the response varied. A Cuban protocol eliminated symptomatic individuals from 
their predictive testing protocol e43, e44, while other teams proceeded with predictive testing if 
clients perceived themselves as asymptomatic e8, e11, e21, e25, e34, e43, e45. Testing was deferred in 
some studies if high risk of future clinical distress e5, e11, e13, e21, e34, e36, e44, e49, e65, problematic 
motivation e5, e22, e26, e30, e65, or the absence of a support system e5, e49, e65 were identified. One 
case series highlighted three situations where individuals still proceeded with predictive 
testing despite having high-risk psychopathology e26. The testing process included close 
interaction with the clients’ psychiatric care team, and the outcome was successful in two of 
three cases e26. In the one study that discussed neurological and psychological assessments in 
reproductive testing, a couple’s request for IVF could be rejected if symptoms were present 
in a parent and the couple seemed unable to provide a stable home environment e37. 
Five studies highlighted the need for increased training for those working in primary care e19, 
e24, e67, psychiatry e16, e25, and neurology e16. The value of having certain providers in the team 
was formally evaluated in three studies e5, e8, e35. In one study, most clients were satisfied with 
their neurologist appointment, particularly those who consulted a neurologist before, 
compared to after, receiving predictive testing results e35. Although instruments to assess 
anxiety, depression, and other psychopathology informed risk of post-test distress e13, e20, e36, 
formal psychiatric testing provided more information than a questionnaire in one study e5. In 
one practice trialed in a clinical setting, a psychologist or psychiatrist was involved in a 
clinical case conference where they never met the client but discussed the case in detail 
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before testing and results disclosure e8. This supported both the client and clinician 
throughout the predictive testing process e8. 
(ii) The number of appointments 
Up to four pre-testing appointments were required in some predictive testing protocols, and 
one study each reported a minimum of one appointment pre-testing for diagnostic e68 and 
reproductive testing e21 (Table 4). After predictive testing results disclosure, additional 
appointments to further educate about the condition, and discuss risk perception and beliefs 
was recommended in two studies e1, e32. Sixteen studies encouraged the client to attend short 
or longer-term psychological follow-up sessions, either if a pathogenic variant was confirmed 
e24, e25, e47, regardless of the result e8, e11, e12, e15, e21, e28, e34, e36, e42, e44, e45, e61, e67, or if requested or 
required based on pre-test discussions e22, e33, e34. Acceptance of follow-up varied with up to 
80% of participants choosing to proceed with post-test psychological follow-up in two studies 
on predictive testing e22, e47, and none proceeding in two other studies in predictive e11 and 
reproductive testing e7.  
In two studies, clients provided positive feedback about the counseling, support, and 
information received throughout the structured protocol e34, e36. However, negative feedback 
was provided in nine studies e10-e12, e14, e21, e28, e34, e36, e67. Some clients were deterred by the 
length, complexity, rigidity, or content of the protocol (including total duration and number 
of consultations) e10-e12, e14, e21, e28, e34, e36, e67, particularly if they had already decided to proceed 
with testing e10, e14. Others were concerned that the psychological assessments pre-testing 
were unnecessary or that testing would be withheld based on the clients’ psychological state 
e11, e21, e28, e36. Consequently, fourteen papers suggested predictive testing be conducted in a 
more individual, flexible way by adapting the protocol to the specific needs, information 
processed and decision-making of the client e12, e15, e17, e22, e27, e28, e33, e34, e42, e43, e45, e51, e61, e62. 
Adaptations included reducing the number of appointments e27, e34, e43, e51, e61, tailoring the 
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content e27, e28, e34, e51, e61 or adapting the psychological support provided to each individual’s 
needs e33, e34. Still, no papers examined whether the number of pre- and post-test counseling 
sessions made a difference to outcomes. One UK series of studies trialed a new practice of 
support post-testing, with a novel standalone genetic counseling narrative group approach for 
individuals with a negative HD predictive test result e38 and a positive HD predictive test 
result e39, e40, as well as their partners e40. The majority of participants were positive about the 
group session being a safe way to share experiences in a structured way e40, discuss difficult 
emotions, highlight coping resources and felt a sense of community e38, e39.  
(iii) The requirement of a support person 
Variations regarding the requirement of a support person throughout the testing process were 
reported in 14 papers (Table 4). Some papers cautioned that the support person might require 
attention, support, or information, particularly if their first attendance is at the client’s results 
appointment e7, e19, e21, e24, e25, e65. One study suggested that support should not be sought from a 
relative who is having predictive testing concurrently, as this could create further anxiety e12. 
A support person may also adopt the decision-making role, as described by one case study of 
a patient with ALS and a family history of HD, whose wife was given decision-making 
capacity regarding HD predictive testing given his terminal condition [56]. No included 
studies formally evaluated the effect of having a support person (or not). Clients in one study 
provided negative feedback on the mandatory requirement of having a support person present 
at the results appointment e28. 
(iv) Barriers to accessing genetic counseling and testing 
Eleven studies described travel distance and time as barriers to accessing genetic counseling 
or testing e11, e12, e18, e23, e27-e29, e36, e62, e64 or adequate support throughout the process e28. 
Geographical barriers were addressed by conducting sessions by telephone or telehealth as 
part of a regular protocol or depending on client preference e15, e21, e37, e48, e49, e53. In other 
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studies, home visits e23 or satellite clinics e29 were conducted, a local health provider was 
upskilled so that remote testing and counseling would be available e15, e28, or multiple 
appointments were arranged on the same day for one client e18 or multiple relatives e23, e62. No 
adverse effects of these modifications were reported, but only two studies evaluated these 
practices. In one, those who received results by telephone and experienced difficulty 
afterwards suggested it would not have helped to attend in person e48. In the other, there were 
no significant differences concerning the quality of care, information, counseling, and support 
provided during the predictive testing process between those who used telehealth with a local 
health provider and those who attended an in-person appointment e15. 
Clients experienced difficulty accessing appropriate support or information in seven studies 
e18, e23, e41, e45, e49, e62, e64. To address this barrier, educational materials were developed with the 
community in their preferred language e18, e41, e62, clients were given funding support to attend 
appointments e18, and the team met with local physicians to educate about genetic risk and 
health resources e62. No studies evaluated the differences in access to or uptake of testing 
before and after implementing these new practices. One educational website was piloted with 
at-risk individuals, health providers and other stakeholders, and positive feedback was 
received e41.  
Eight studies noted different laws were present that may be a barrier for accessing genetic 
counseling and testing. This included discrimination based on genetic testing results e42, e49, 
access to termination of pregnancy for genetic disorders e43, e45, access to direct, exclusion or 
non-disclosure reproductive testing e37 and obligations to inform relatives about genetic 
results or family medical information (before or after death) e22, e42, e50, e56.  
Client-specific barriers to accessing predictive or reproductive testing included the presence 
of an intervening at-risk relative e21, e30, e42, e60 or where there were identical twins e42. Three 
practices explicitly excluded individuals at 25% risk from their predictive testing protocol if 
Crook 12 
 
the intervening relative was available for testing e42, e43, e45. Others used strategies to 
encourage relatives to consider testing, including: suggesting the client discuss testing with 
their relative with the hope that they proceed first e21, e30, e42, e60; offering to meet the relative to 
involve them in the pre-test counseling and ensure they are aware of the consequences of the 
client having testing first e30; or to undergo testing alongside their twin sibling e42. These 
strategies were useful in two cases e42. Where these strategies were unsuccessful, clients 
signed a confidentiality agreement to ensure non-disclosure (to maintain the intervening 
relative’s right not to know) e42, e60. To minimize adverse outcomes in a case where the 
intervening relative believed they would commit suicide if they knew they were affected, 
grandparental blood samples were also collected for use in reproductive testing before 
revealing the test outcome e60. The possible adverse effect of testing clients at 25% risk was 
highlighted in one study: of four intervening at-risk relatives who had been informed of their 
positive status, three became depressed, and one committed suicide after the result was 
disclosed e30.  
(v) The activities involved in genetic counseling practice 
The activities involved in current genetic counseling and testing practice for LONDs are 
summarized in Table 5. The activities are divided between the four defined goals of genetic 
counseling 5-7. Some activities only concerned certain types of genetic testing, while others 
were consistent across multiple testing settings. All reported activities were performed in one 
or more predictive testing practices (35/35), whereas fewer were reported in diagnostic 
(23/35) and reproductive testing (19/35).  
(vi) Addressing the goals of genetic counseling 
Eighteen papers included activities that addressed all four goals of genetic counseling (Table 
6). The education goal was the most commonly included goal across all papers (52/68), 
closely followed by the counseling (49/68) and support (45/68) goals. There were no major 
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differences between the goals addressed and testing types, with the number and type of goals 
addressed spread evenly across each testing type. 
DISCUSSION 
Our primary aim of this systematic review was to establish a comprehensive understanding of 
current genetic counseling and testing practices for LONDs. We identified 61 different 
studies published in 68 papers from 19 countries that described genetic counseling and testing 
practices for LONDs over the past decade. Studies varied greatly in setting and design. HD 
was the most common condition studied, and predictive testing was examined more 
frequently then diagnostic or reproductive testing. Although some practices had shared 
aspects, there were many novel or inconsistent approaches to genetic counseling for LONDs. 
For predictive testing, a multidisciplinary care approach was taken in most studies with 
neurologists, geneticists and psychologists being the most common health providers involved. 
Health provider decision-making about genetic testing varied in the presence of ethical 
issues, high-risk psychopathology, and neurological symptoms. In some predictive testing 
protocols, up to four pre-test counseling sessions were required. Attendance at follow-up 
sessions post-testing was variable. Overall, there was an emerging focus on a client- or 
family-centered, flexible approach to genetic counseling for LONDs to address negative 
feedback, barriers to accessing testing and possible harms. However, few innovative 
modifications to practice were evaluated. Our secondary aim was to identify to what extent 
current practices address the established goals of genetic counseling. Our findings indicate 
that current genetic counseling practices rarely address the four published genetic counseling 
goals.  
Given most studies focused on predictive testing, it is difficult to draw any firm conclusions 
regarding genetic counseling practices for diagnostic and reproductive testing. There are 
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several possible explanations for fewer studies in these two areas. In diagnostic testing, those 
undergoing testing will demonstrate some symptoms suggestive of a LOND. Therefore, both 
patients and their health providers may think a genetic test may guide medical management 
and access to emerging targeted clinical trials 32, 33. Still, as the diagnostic testing guidelines 
for HD note, the confirmation of a disease diagnosis may affect both the patient and their 
family 19. Therefore, genetic counseling is an essential part of diagnostic testing. Depending 
on the needs and expectations of the patient and their family, they may need to be informed 
of hereditary risks, assisted with adjusting to the diagnosis and familial risk, or provided with 
access to predictive or reproductive testing, further support, information, and resources 19, 34. 
One crucial difference between LONDs is that for entirely heritable conditions, like HD, a 
diagnosis would only be confirmed if a pathogenic variant was detected. For partially 
heritable conditions, like FTD, genetic testing may be performed separately to the diagnosis 
of the LOND 35. Therefore, different genetic counseling practices may be required depending 
on the patient’s diagnostic status and the likelihood of confirming a pathogenic variant 18, 19. 
The low number of studies on reproductive testing may be explained by its low uptake rate 
overall, as clients may choose other family planning options like conceiving naturally or 
choosing not to conceive e54, 36. There may also be legal barriers to accessing reproductive 
testing or termination of pregnancy e37, e43, e45. Further investigation in both diagnostic and 
reproductive testing for LONDs is warranted.  
The involvement of a multidisciplinary team was consistent across predictive testing 
practices, which is supported by the current guidelines 13, 15-18. The low number of studies 
including genetic counselors suggests this health professional group may be under-utilized.  
An explanation could be local barriers to incorporating genetic counselors in practice (health-
care system disparities, cultural differences, or the global shortage of genetic counselors) 3, 30. 
The involvement and role of different health providers were difficult to distinguish in many 
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studies. Only three studies evaluated certain specialist health providers, highlighting the 
benefits of neurologists, psychiatrists, or psychologists in a predictive testing team e5, e8, e35. 
Where reported, neurological and psychiatric/psychological assessments in predictive testing 
were more commonly mandatory, which contrasts with the HD predictive testing guidelines, 
where these assessments are considered important but not required in a predictive testing 
protocol 13. In the presence of high-risk psychopathology, neurological symptoms, or ethical 
issues in predictive testing, health provider decision-making about proceeding with testing 
varied. There was no apparent trend to suggest that responses differed between health 
provider specialty types. Further research is required to compare the provision of genetic 
counseling for LONDs between different health providers and to assess whether this has any 
effect on patient outcomes and testing decision-making. 
In some predictive testing protocols, up to four pre-testing appointments were required, and 
the protocol length was frustrating for some clients e11, e12, e21, e28. The success and uptake of 
follow-up post-testing varied between studies, despite being encouraged. Many studies 
highlighted the need for an individualized, flexible, client-centered approach to genetic 
counseling practice given that a client who attends for genetic testing and counseling has a 
unique lived experience and motivation for proceeding with testing e19, e21, e26, e42, e44, e51, e54, e60, 
e64. Financial, geographical, or language barriers to accessing testing or appropriate support 
and information may also need addressing e18, e23, e41, e45, e49, e62, e64. Therefore, clients may or 
may not require a neurological or psychological/psychiatric assessment, a support person at 
appointments, multiple pre- or post-testing consultations, or further resources, support, or 
information. Genetic counseling practices should also consider the possible implications of 
genetic testing for the client’s family, given the potential risk of harm for relatives e30, e60. 
Client and family-centered considerations are reflected in the current HD predictive testing 
guidelines 13. Predictive testing performed within an integrated counseling protocol is 
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considered safe in several studies, with few major adverse events reported in clients e34, 12, 37. 
Pre-test discussions are thought to protect against negative psychological effects post-testing 
e14, e21, e67. Few included studies assessed the effectiveness and safety of a modified versus 
more traditional genetic counseling protocol, highlighting an area of necessary evaluation in 
the future that is supported by a previous quality assessment on genetic counseling for 
predictive testing of LONDs 38. 
Of the studies that did assess innovative genetic counseling practices, there was evidence to 
support telephone or telehealth consultations for clients to access more flexible testing and 
support locally e15, e48. In contrast, the predictive HD testing guidelines, published in 2013, 
state that results should 13. Perhaps this recommendation requires review, given emerging 
data on the provision of telehealth during the ongoing pandemic 39, 40. Health providers’ time 
may become more limited if a clinical trial for asymptomatic patients becomes available, and 
interest in predictive testing increases e29, e57. Additional novel practices, such as using an 
educational website pre-testing e41 or group sessions post-testing e38-e40, may also help manage 
health provider time. Other innovative approaches to genetic counseling practice should be 
considered and evaluated, with client safety at the forefront.  
All genetic counseling activities were identified in one or more predictive testing study. In 
comparison, less activities were identified in diagnostic and reproductive testing (although 
fewer studies were in these areas). The majority of current practices did not meet all four 
genetic counseling goals, raising the possibility that current practices do not fulfill the 
required goals, or that the goals need to be adapted to align with the specific practices 
required for LONDs. Firm conclusions or implications for practice are premature, given that 
some study objectives assessed one aspect of genetic counseling practice only (e.g. 
knowledge, or motivations to undergo testing), few practices were formally evaluated, 
practices were inconsistently reported, and the overall strength of evidence is low. Findings 
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do, however, highlight gaps in our knowledge and considerations for further research in 
genetic counseling and testing for LONDs. The identified genetic counseling activities may 
provide a basis for the possible activities required in a model of genetic counseling service 
delivery for LONDs, addressing all four genetic counseling goals.  
Limitations 
Limitations exist regarding the individual articles and study selection methodology. Although 
several genetic counseling practices were identified, few were formally trialed or evaluated. 
The inclusion criteria resulted in the omission of works published in different languages, 
before 2009 and presented outside peer-reviewed journals. Consequently, our findings may 
have been affected by selection and publication bias. No randomized control trials were 
identified, and we did not exclude eight low-quality studies, affecting the robustness of the 
synthesis. We grouped LONDs due to their shared similarities, and therefore condition-
specific issues were likely present but not extracted.  
Overall, the strength of evidence in these studies was low. There was considerable 
heterogeneity across the included studies in terms of study design, populations (and response 
rate), and outcomes, which became a critical issue in making sound conclusions regarding 
implications for practice. The authors AC and ROS used their knowledge as experienced 
genetic counselors to combine and allocate genetic counseling activities amongst the four 
genetic counseling goals, which may have led to a bias toward presenting the aspects of 
practice considered important to a genetic counselor. We assessed whether included practices 
addressed the goals of genetic counseling, and we could not definitively know whether 




Current genetic counseling and testing practice for LONDs is varied and informed by local 
laws and practices, resources, and the availability of different health providers. Few practices 
addressed all four goals of genetic counseling. A flexible, multidisciplinary approach to 
genetic counseling that is adaptable to the client and their family’s needs continues to 
emerge. Evaluations of novel approaches to care are limited and provide an opportunity for 
further evaluation. Possible future study areas should focus on diagnostic and reproductive 
genetic testing and counseling practices, and the role and use of different health providers. As 
genetic and genomic testing becomes a routine part of care for patients with LONDs (and 
their relatives), health providers must balance their limited time and resources with ensuring 
that clients can be safely and effectively counseled. Increased involvement of genetic 
counselors or innovative approaches to providing genetic counseling may fulfill this need. 
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Table 1 Inclusion and exclusion criteria 
INCLUSION EXCLUSION 
Population 
• Health providers of genetic testing and/or counseling 
for late-onset neurodegenerative diseases (LONDs*) 
OR 
• Adults with or at risk of a LOND, or medical 
guardians of adults with a LOND 
• Childhood-onset, lower penetrance, autosomal 
recessive or X-linked inherited diseases 
• Included population not easily stratified from 
excluded population (e.g. if there are multiple 
diseases or ages included)  
Intervention 
• Any aspect of genetic counseling practice, both 
before, during, or after genetic testing. This includes 
diagnostic testing, predictive or pre-symptomatic 
testing, and reproductive testing 
• Laboratory methods 
• Research genetic testing where the result is 




• Key components and activities of the genetic testing 
or counseling process including the role and 
involvement of health providers  
• Goals of genetic counseling or testing including 
experience, outcomes, and recommendations that 
inform practice (Goals include any of the four goals 
of genetic counseling: interpretation, education, 
counseling, support) 
• Outcomes not specific to the genetic counseling 
or testing process 
• Likelihood of detecting a pathogenic variant, 
population frequencies, phenotypic data, uptake 
rate of testing, and family communication, without 
any information on clinical genetic testing or 
counseling practices 
Study design and context 
• Any method of peer-reviewed research  
AND  
• Published after 1 January 2009  
• Non-peer-reviewed papers, editorials, grey 
literature, non-systematic reviews, book chapters 
or dissertations 





• Published in English, from worldwide 
that do not explicitly stem from research or 
clinical experience 
*LONDs that were included in this study were expected to have similar potential psychological sequelae to each 
other as they had the following characteristics: mostly adult-onset, neurodegenerative, high penetrance, and 
autosomal dominant inheritance. This included (but was not limited to) Huntington’s disease, amyotrophic lateral 
sclerosis, frontotemporal dementia, Alzheimer’s disease, genetic prion diseases, CADASIL (cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy), muscular dystrophies, hereditary 
spastic paraplegias, spinocerebellar ataxias or neuropathies (including Charcot-Marie-Tooth disease). 
Crook 22 
 








Alzheimer* disease OR Huntington* disease OR chorea OR prion 
disease OR CADASIL OR muscular dystroph* OR hereditary spastic 
paraplegia OR cerebellar ataxia OR Charcot Marie Tooth OR familial 
amyloid* neuropathy OR degenerative disease OR 
neurodegenerative disease OR Amyotrophic Lateral Sclerosis OR 
motor neuron* disease OR Frontotemporal Dementia OR 





#Complete list of search terms available in Table e-1 




Table 3 Summary of included papers 
Characteristics Number of 
papers 
References 
Conditions investigated*#   
Huntington’s disease (HD) 41 e1-e41 
Spinocerebellar ataxias (SCAs- all subtypes) 12 e8-e12, e36, e42-e47 
Amyotrophic lateral sclerosis/Frontotemporal dementia 
(ALS/FTD) 
11 e26, e27, e48-e56 
Familial amyloid polyneuropathy (TTR-FAP) 7 e9-e13, e33, e36 
Unspecified disease type or included >6 LONDs  5 e57-e61 
Alzheimer’s disease (AD) 3 e62-e64 
Prion disease 2 e65, e66 
Cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy 
(CADASIL) 
2 e36, e67 
Facioscapulohumeral muscular dystrophy (FSHD) 1 e68 
Intervention type#   
Diagnostic genetic testing 17 e3, e17, e19, e23, e27, e29, e32, e50, e52, e53, e55, 
e56, e58, e62, e63, e65, e68 
Predictive genetic testing 58 e1-e6, e8-e15, e17-e19, e21-e36, e38-e45, e47-e52, 
e55, e57, e59-e62, e64-e68 
Reproductive genetic testing 11 e4, e7, e16, e21, e37, e42, e43, e46, e54, e55, e60 
Unspecified genetic testing type 1 e20 
Main author location(s)#   
Europe 33 e4, e5, e7-e10, e12-e14, e17, e22, e24, e25, e30, e33-
e40, e45, e47, e50-e52, e56-e58, e61, e66, e67 
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North America 29 e1-e3, e6, e15, e16, e19-e21, e23, e26-e29, e31, e32, 
e41-e44, e46, e48, e49, e53, e54, e62-e65 
South America 2 e11, e45 
Asia 2 e59, e68 
Africa 1 e18 
Australia 2 e55, e60 
Source of genetic counseling practice   
Practice sourced from clinical experience 32 e4, e16, e18, e21-e23, e26, e27, e29-e31, e34, e36, 
e37, e42-e45, e47, e50-e53, e55, e56, e58-e60, e62, 
e65, e67, e68 
Practice trialed in clinical setting  6 e8, e15, e20, e38-e40 
Practice recommended from clinical research  20 e1, e2, e5-e7, e9-e14, e24, e25, e33, e35, e48, e49, 
e57, e63, e66 
Practice recommended from non-clinical research 10 e3, e17, e19, e28, 32, e41, e46, e54, e61, e64 
Study type#   
Qualitative 24 e1-e3, e7, e9, e10, e12, e14, e17, e19, e24, e25, e28, 
e30, e32, e38-e41, e48, e54, e57, e64, e66 
Case series 21 e4, e8, e9, e11, e18, e21, e22, e26, e29, e30, e42-e45, 
e49, e51, e58, e63, e66-e68 
Cohort study 14 e1, e5, e6, e11, e13-e15, e20, e33, e34, e36, e37, e47, 
e67 
Case study 11 e23, e27, e45, e50, e51, e55, e56, e60, e62, e65, e68 
Cross-sectional survey 9 e16, e31, e35, e41, e46, e52, e53, e59, e64 
Delphi survey 1 e61 
Before and after study 1 e38  
Risk of Bias assessment   
>0.90 50 e3-e13, e15-e17, e19-e21, e23-e27, e29, e31-e33, e35-
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e40, e42-e47, e50, e52, e53, e55-e57, e59-e61, e65, 
e67, e68 
0.80-0.89 10 e1, e14, e18, e34, e41, e48, e54, e58, e62, e64 
0.70-0.79 5 e2, e22, e28, e49, e63 
0.60-0.69 1 e30 
0.50-0.59 2 e51, e66 





Table 4 Variations among genetic counseling and testing practices for LONDs 





References for each testing type 
Diagnostic 
testing 
Predictive testing Reproductive 
testing 
Health providers involved 
within testing team 
    
Neurologist 24 e29, e53, e56, e58, 
e68 
e6, e8, e12, e14, e18, e22, e26, e27, e29, 
e34, e35, e42-e45, e47-e49, e56, e59, 
e67, e68 
e42  
Geneticist 23 e56, e58, e68 e8, e11, e14, e18, e21, e22, e30, e34, 
e35, e42, e44, e45, e48, e49, e51, e59, 
e61, e66-e68 
e37, e42 
Psychologist 21 e56, e58 e8, e11, e14, e15, e18, e21, e22, e30, 
e34, e42-e45, e47, e51, e59, e61, e66, 
e67 
e42  
Genetic counselor 15 e29, e53, e68 e15, e21, e26, e27, e29, e42-e45, e48, 
e49, e59, e61, e68 
e42 
Psychiatrist 7 e29 e5, e8, e22, e26, e29, e45, e59  
Nurse 7 e29, e53 e18, e22, e29, e30, e59, e61  
Social worker 6 e53 e22, e26, e42, e45, e61 e42 
Molecular biologist/ Laboratory 
geneticist 
3  e8, e22, e61  
Family physician 2  e8, e43   
Medical doctor (other or 
unspecified) 
2  e42, e61 e42 
Obstetrician/ gynaecologist 2   e21, e37 
Bioethicist 1  e42 e42 
Neuropsychiatrist 1 e29 e29  
Crook 27 
 
Neurological assessment     
Mandatory 11 e29 e6, e8, e29, e34-e36, e42-e44, e47, e67  
As needed 5  e11, e21, e22, e45 e37 
Offered 1  e35  
Where possible 2  e15, e28  
Psychiatric/ psychological 
assessment# 
    
Mandatory 16  e5, e8, e11, e12, e14, e21, e26, e30, e42-
e44, e47, e51, e57, e66, e67 
 
As needed 9  e11, e13, e21, e22, e45, e48, e49, e65 e37 
Minimum recommended 
number of appointments 






1 5 e68 e48, e49, e51, e68 e21 
1 + reflection time 3  e14, e21, e22  
2 7  e8, e12, e15, e28, e30, e34, e45  
3 4  e14, e18, e21, e36  




1 17 e68 e14, e18, e45, e48, e49, e51, e68  
1 + follow-up 
encouraged 
19  e1, e8, e11, e12, e15, e21, e24, e25, e28, 
e32, e34, e36, e42, e44, e45, e47, e61, 
e67 
e7 
Support person+ at 
appointments 
    
At results appointment 6  e11, e12, e15, e28, e45, e67  
Strongly encouraged 5 e27, e56 e12, e21, e28  
Optional 3  e11, e21, e49  
Involvement of both members 3   e37, e43, e54 
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of a couple 
Mandatory 1  e45  
#Psychological and psychiatric assessments have been combined as many studies were unclear about which 
health provider was involved, +A support person may be a family member or peer 
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Table 5 Activities involved in genetic counseling and testing practices for LONDs in accordance with the four defined goals of genetic 
counseling, and divided between testing types 
Genetic counseling activity Number of 
papers 
References for each testing type 
Diagnostic 
testing 
Predictive testing Reproductive 
testing 
Goal of genetic counseling 1: Interpretation of family and medical histories to assess the chance of disease occurrence or recurrence 
Assess risk of client and other relatives carrying a pathogenic variant, incorporating family- 
and variant-specific information, penetrance and pathogenicity in risk assessment 
17 e19, e27, e53, e56, 
e62, e65, e68 
e4, e19, e24, e25, e27, e30, e42, e44, e45, 
e49, e51, e62, e65, e67, e68 
e4, e42 
Gather family history and any relevant family genetic testing reports 15 e3, e23, e53, e58, e62, 
e63, e68 
e3, e8, e15, e21, e23, e27, e30, e44, e57, 
e62, e65, e68 
  




Engage in interdisciplinary discussion and literature review 9 e58 e8, e22, e26, e27, e42, e49, e59, e61 e42 
Goal of genetic counseling 2: Education about the natural history of the condition, inheritance pattern, testing, management, prevention, support, resources and 
research 
Provide condition-specific information about:  
- natural history (main clinical symptoms, early and late manifestations, prognosis, 
mode of inheritance, all possible genetic testing results) 
- uncertainties (variable age at onset, severity, progression, penetrance, mostly 
27 e23, e32, e50, e53, 
e55, e56, e58, e68 
e5, e8, e9, e11, e15, e21, e23, e26, e28, 
e32, e35, e36, e41, e45, e49, e51, e55, e57, 




limited prevention and treatment options) 
Discuss the use, privacy and storage of results now and in future (e.g. whether they would 
form part of the medical record, able to be shared in case of death) and distinguish 
between research and clinical care 
17 e50, e56, e58, e62, 
e65 
e11, e21, e22, e27, e31, e42-e45, e49, e50, 
e57, e61, e62, e65 
e43 
Advise that knowledge about the condition could inform family planning and detail all of the 
reproductive testing options available 
13 e68 e41, e43, e45, e49, e51, e57, e65, e67, e68 e7, 16, e37, e46 
Detail the genetic testing process and protocol 12  e12, e15, e36, e41, e43-e45, e48, e49, e57, 
e61, e67 
e43 
Review possible clinical implications of testing on other relatives 12 e53, e56, e68 e24, e28, e30, e41, e42, e49, e57, e60, e68 e7, e42 
Provide information in oral, visual and written format, including online information 12 e3, e62 e3, e14, e18, e21, e22, e30, e41, e57, e61, 
e62 
e37, e46 
Gain informed consent in writing 11 e50, e56, e58, e68 e8, e21, e22, e27, e44, e49, e68 e37 
Identify and address informational misconceptions, myths and prejudgments 11 e3, e23, e32 e3, e10, e12, e23, e27, e32, e36, e45, e57, 
e64, e65 
 
Ensure all potential consequences of testing understood by client 7 e3 e1, e3, e12, e26, e27, e51, e67  
Discuss possible other implications of testing for the client and relatives (e.g. risk of 
discrimination in insurance, misattributed paternity) 
7 e65, e68 e21, e28, e42, e49, e51, e65, e68  
Review limitations of currently available genetic testing 5 e55, e68 e4, e49, e55, e57, e68 e4, e55 
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Review the results of any risk assessment performed as part of the workup 4 e68 e11, e45, e57, e68  
Provide information about possible research studies available  1  e41  
Goal of genetic counseling 3: Counseling to promote informed choices in view of risk assessment, family goals, ethical and religious values. 
Discuss motivations for proceeding with testing, including decision-making process, and 
clarify expectations where required 
20 e32 e5, e6, e8, e9, e14, e21, e22, e26, e29, e32-
e34, e36, e44, e45, e49, e51, e57, e65, e67 
 
Assess psychosocial readiness to undergo testing and ability to cope with testing process 
and/or either possible result, including adaptation mechanisms, psychological history, 
current substance abuse/ stressors/ changes in mood/ cognitive functioning 
20 e3 e3, e5, e8, e11, e13, e15, e21, e26, e33, 
e34, e36, e44, e45, e47, e49, e51, e65-e68 
 
Assess and address family dynamics and communication (e.g. whether the client plans to 
communicate any type of result with relatives, suggesting further family discussion before 
proceeding with testing and/or supporting the client in familial communication) 
16 e50, e62, e65 e8, e9, e21, e22, e26, e27, e42, e44, e45, 
e49, e51, e57, e61, e62, e65 
e42 
Confirm the client is making an autonomous choice 13  e2, e5, e8, e11, e14, e15, e21, e24, e34, 
e42, e49, e51, e57 
e21, e42 
Review lived experience of disease (e.g. time elapsed since awareness of family 
diagnosis, whether the client has direct experience and understanding of the disease) 
12 e17 e8, e17, e21, e22, e24, e26, e34, e49, e51, 
e57, e67 
e54 
Discuss the voluntary nature of undergoing testing including the right to opt-out at any time 
and alternative options (e.g. DNA banking, deferring testing, undergoing testing but not 
receiving the results) 





Assess access to social support within and outside the family  10  e13, e15, e26, e28, e42, e45, e47, e49, e51, 
e57 
e42 
Encourage the client to consider possible responses and effects of testing on other 
individuals (e.g. support person, partners, family members) including the possibility of 
various results scenarios between different family members 
9 e3 e3, e24-e26, e49, e51, e57, e61 e7 
Review the timing of testing, perceived advantages and disadvantages of proceeding (or 
not) 
8  e9, e12, e24, e26, e44, e45, e49, e57  
Review common emotional responses and possible psychological effects of testing 8  e26, e34, e36, e41, e47, e49, e65 e7 
Ensure all potential consequences have been considered 7 e3 e3, e12, e25-e27, e51, e67   
Discuss attitudes and values towards family planning options including termination of 
pregnancy 
4  e60 e7, e21, e43, e60 
Provide additional consultations when requested and space for the client to raise 
questions, doubts or concerns 
3  e36, e48, e49  
Goal of genetic counseling 4: Support to encourage the best possible adjustment to the disorder in an affected family member and/or to the risk of recurrence of 
that disorder 
Offer counseling or psychological support to client, other family members and support 
person both pre-, during and post-testing to facilitate adjustment, integrate results into 
daily life and minimize potential adverse effects 
30 e3, e19, e65, e66 e1, e3, e6, e11, e13, e15, e19, e21, e22, 
e24-e26, e30, e33, e34, e38-e40, e42, e43, 
e45, e47-e49, e51, e61, e65-e67 
e7, e21, e43 
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Offer support or information resources throughout (e.g. online information, contact details 
or referral to relevant organisations) 
10 e3, e23, e62, e65 e3, e14, e15, e23, e30, e41, e49, e61, e62, 
e65 
 
Provide an opportunity for the client to express and explore their emotional reaction to the 
result 
7  e12, e15, e21, e24, e26, e51, e65  
Offer medical follow-up to pathogenic variant carriers  7  e13, e21, e25, e43, e45, e61, e67  
Preferably the same health provider(s) meet client post-testing 5  e8, e11, e22, e57, e67  
Request for feedback on the process (e.g. satisfaction with the protocol, general 
suggestions, if they would recommend it to other persons) 
2  e5, e36  
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References for each testing type# 
Diagnostic 
testing 




Goal of genetic counseling addressed in study# 
Interpretation 32 e3, e19, e23, e27, e29, 
e52, e53, e55, e56, e58, 
e62, e63, e65, e68  
e3, e4, e8, e15, e19, e21-e23, e26-
e30, e35, e42-e45, e49, e52, e55, 
e57, e60-e62, e65, e68  
e4, e21, e37, e42, e43, 
e55, e60 
 
Education 52 e3, e19, e23, e29, e32, 
e50, e53, e55, e56, e58, 
e62, e65, e68 
e1, e3-e5, e8-e12, e14, e15, e18, 
e19, e21-e24, e26-e32, e35, e36, 
e41-e45, e48-e51, e55, e57, e60-
e62, e64, e65, e67, e68 
e4, e7, e16, e21, e37, 




Counseling 49 e3, e17, e29, e32, e50, 
e56, e58, e62, e65 
e2, e3, e5, e6, e8, e9, e11-e15, 
e17, e21, e22, e24-e30, e32-e34, 
e36, e41-e45, e47-e49, e51, e57, 
e59-e62, e65-e68 




Support 45 e3, e17, e19, e23, e58, 
e62, e65 
e1, e3, e5, e6, e8, e11-e15, e17, 
e19, e21-e26, e28, e30, e33, e34, 
e36, e38-e45, e47-e49, e51, e57, 
e59, e61, e62, e65-e67 
e7, e21, e42, e43 e20  
Number of goals of genetic counseling addressed in study# 
4 18 e3, e58, e62, e65 e3, e8, e15, e21, e22, e26, e28, 
e30, e42-e45, e49, e57, e61, e62, 
e65  
e21, e42, e43   
3 18 
  
e19, e23, e29, e56 e5, e11, e12, e14, e19, e23, e24, 
e27, e29, e36, e41, e48, e51, e60, 
e67, e68 
e7, e60  
2 21 e17, e32, e50, e53, e55, 
e68 
e1, e4, e6, e9, e13, e17, e25, e32-
e35, e47, e50, e55, e59, e66 
e4, e37, e54, e55 e20  
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Duplicates removed  
(n=3959) 
Title and abstracts screened  
(n=8253) 
Records excluded  
(n=7948) 
Full-text screened  
(n=305) 
Records excluded  
(n=237) 
Reasons: 
1. Duplicate or erratum (n=2) 
2. Full text not in English (n=19) 
Inappropriate: 
3. Year of publication (n=1) 
4. Study design/context (n=160) 
5. Population (n=18) 
6. Intervention (n=13) 
7. Outcome (n=24) 
 
Papers included in review 
(n=68) 




Table e- 1 Search terms used 
Search terms Medline Embase CINAHL PsycINFO 
1. Genetic counsel* Genetic Counseling/ genetic counselling/ TI genetic counsel* OR AB 
genetic counsel* 
TI genetic counsel* OR AB 
genetic counsel* 
Genetic counsel*.tw. Genetic counsel*.tw. (MH "Genetic Counseling") DE "Genetic Counseling" 
2. Genetic testing : Gene* 
test OR Genetic test* OR 
gene test* 
 
(gene* test or gene* test or 
genetic test* or genetic test* or 
gene test* or gene test*).tw. 
(gene* test or gene* test or 
genetic test* or genetic test* 
or gene test* or gene test*).tw.  
 
TI gene* test OR AB gene* test 
OR TI genetic test* OR AB 
genetic test* OR TI gene test* OR 
AB gene test*  
TI gene* test OR AB gene* test 
OR TI genetic test* OR AB 
genetic test* OR TI gene test* OR 
AB gene test*  
Genetic Testing/ DE "Genetic Testing"  
3. Genetic screening: Gene* 
screen OR genetic 
screen* OR gene screen* 
 
(gene* screen or gene* screen 
or genetic screen* or genetic 
screen* or gene screen* or 
gene screen*).tw. 
(gene* screen or gene* screen 
or genetic screen* or genetic 
screen* or gene screen* or 
gene screen*).tw. 
TI gene* screen OR AB gene* 
screen OR TI genetic screen* OR 
AB genetic screen* OR TI gene 
screen* OR AB gene screen*  
TI gene* screen OR AB gene* 
screen OR TI genetic screen* OR 
AB genetic screen* OR TI gene 
screen* OR AB gene screen* 
Genetic screening/ (MH "Genetic Screening")  
4. Amyotrophic Lateral 
Sclerosis 
Amyotrophic Lateral Sclerosis/ amyotrophic lateral sclerosis/ TI amyotrophic lateral sclerosis 
OR AB amyotrophic lateral 
sclerosis 
TI amyotrophic lateral sclerosis 






(MH "Amyotrophic Lateral 
Sclerosis") 
DE "Amyotrophic Lateral 
Sclerosis” 
5. motor neuron* disease Motor Neuron Disease/ motor neuron disease/ (MH "Motor Neuron Diseases") TI motor neuron* disease OR AB 
motor neuron* disease motor neuron* disease.tw. motor neuron* disease.tw. TI motor neuron* disease OR AB 
motor neuron* disease 
6. lou gehrig* disease lou gehrig* disease.tw. lou gehrig* disease.tw. TI lou gehrig* disease OR AB lou 
gehrig* disease 
TI lou gehrig* disease OR AB lou 
gehrig* disease 
7. Frontotemporal Dementia Frontotemporal Dementia/ frontotemporal dementia/ (MH "Frontotemporal Dementia") TI frontotemporal dementia OR 
AB frontotemporal dementia Frontotemporal Dementia.tw. Frontotemporal Dementia.tw. TI frontotemporal dementia OR 
AB frontotemporal dementia 







(MH "Frontotemporal Lobar 
Degeneration") 
TI frontotemporal lobar 
degeneration OR AB 
frontotemporal lobar degeneration Frontotemporal Lobar 
Degeneration.tw. 
TI frontotemporal lobar 
degeneration OR AB 
frontotemporal lobar degeneration 
9. Dementia DEMENTIA/ Dementia/ (MH "Dementia") DE "Dementia" 
Dementia.tw. Dementia.tw. TI dementia OR AB dementia TI dementia OR AB dementia 
10. semantic dementia semantic dementia.tw. Semantic dementia/ DE "Semantic Dementia" 
 
 
semantic dementia.tw. TI semantic dementia OR AB 
semantic dementia 
TI semantic dementia OR AB 
semantic dementia 
11. presenile dementia presenile dementia.tw. 
 
Presenile dementia/ (MH "Dementia, Presenile")  DE "Presenile Dementia" 
presenile dementia.tw. TI presenile dementia OR AB 
presenile dementia 
TI presenile dementia OR AB 
presenile dementia 
12. Pick* disease "Pick Disease of the Brain"/ Pick* disease.tw. (MH "Pick Disease of the Brain") DE "Picks Disease" 
Pick* disease.tw. TI pick* disease OR AB pick* 
disease  
TI pick* disease OR AB pick* 
disease 
13. Pick* dementia Pick* dementia.tw. Pick presenile dementia/ TI pick* dementia OR AB pick* 
dementia 
TI pick* dementia OR AB pick* 
dementia  Pick* dementia.tw. 








TI Pallidopontonigral degeneration 
OR AB Pallidopontonigral 
degeneration 
TI Pallidopontonigral degeneration 
OR AB Pallidopontonigral 
degeneration 
16. pallido ponto nigral 
degeneration 
pallido ponto nigral 
degeneration.tw. 
pallido ponto nigral 
degeneration.tw. 
TI Pallido ponto nigral 
degeneration OR AB Pallido ponto 
nigral degeneration 
TI Pallido ponto nigral 
degeneration OR AB Pallido 
ponto nigral degeneration  
17. Alzheimer* disease ALZHEIMER DISEASE/ Alzheimer disease/ (MH "Alzheimer's Disease") DE "Alzheimer's Disease" 
Alzheimer* disease.tw. Alzheimer* disease.tw. TI Alzheimer* disease OR AB 
Alzheimer* disease 
TI alzheimer* disease OR AB 
alzheimer* disease 
18. Huntington* disease HUNTINGTON DISEASE/ Huntington* disease.tw. (MH "Huntington's Disease")  DE "Huntingtons Disease" 
Huntington* disease.tw. TI huntington* disease OR AB 
huntington* disease 
TI huntington* disease OR AB 
huntington* disease  
19. Huntington* chorea Huntington* chorea.tw. Huntington chorea/ TI huntington* chorea OR AB 
huntington* chorea  
TI huntington* chorea OR AB 
huntington* chorea Huntington* chorea.tw. 
20. huntington disease like huntington disease like.tw. Huntington disease like 
syndrome/ 
TI huntington disease like OR AB 
huntington disease like 
TI huntington disease like OR AB 
huntington disease like 
huntington disease like.tw. 
21. Corticobasal 
degeneration 
Corticobasal degeneration.tw. Corticobasal degeneration/ TI corticobasal degeneration OR 
AB corticobasal degeneration 
DE "Corticobasal Degeneration" 
Corticobasal degeneration.tw. TI corticobasal degeneration OR 
AB corticobasal degeneration 






(MH "Supranuclear Palsy, 
Progressive") 






TI progressive supranuclear palsy 
OR AB progressive supranuclear 
palsy  
TI Progressive Supranuclear 




23. prion disease Prion Diseases/ Prion disease/ (MH "Prion Diseases") TI prion disease OR AB prion 
disease prion disease.tw. prion disease.tw. TI prion disease OR AB prion 
disease 
24. creutzfeldt jakob Creutzfeldt-Jakob Syndrome/ Creutzfeldt Jakob disease/ (MH "Creutzfeldt-Jakob 
Syndrome")  
DE "Creutzfeldt Jakob Syndrome" 
creutzfeldt jakob.tw. creutzfeldt jakob.tw. TI creutzfeldt jakob OR AB 
creutzfeldt jakob 

















Scheinker OR AB Gerstmann-
Straussler-Scheinker 
26. fatal familial insomnia Insomnia, Fatal Familial/ Fatal familial insomnia/ TI fatal familial insomnia OR AB 
fatal familial insomnia  
TI fatal familial insomnia OR AB 
fatal familial insomnia  fatal familial insomnia.tw. fatal familial insomnia.tw. 
27. CADASIL CADASIL/ CADASIL/ (MH "CADASIL") TI cadasil OR AB cadasil 
CADASIL.tw. CADASIL.tw. TI cadasil OR AB cadasil 
28. muscular dystroph* Muscular Dystrophies/ Muscular dystrophy/ (MH "Muscular Dystrophy") DE "Muscular Dystrophy" 
muscular dystroph*.tw. muscular dystroph*.tw. TI muscular dystroph* OR AB 
muscular dystroph* 
TI muscular dystroph* OR 
muscular dystroph* 






(MH "Spastic Paraplegia, 
Hereditary") 
TI hereditary spastic paraplegia 
OR AB hereditary spastic 
paraplegia hereditary spastic 
paraplegia.tw. 
TI hereditary spastic paraplegia 
OR AB hereditary spastic 
paraplegia 
30. spinocerebellar ataxia Spinocerebellar Ataxias/ spinocerebellar ataxia.tw. (MH "Spinocerebellar Ataxias") TI spinocerebellar ataxia OR AB 






Spinocerebellar degeneration/ (MH "Spinocerebellar 
Degenerations")  
TI spinocerebellar degeneration 





TI spinocerebellar degeneration 
OR AB spinocerebellar 
degeneration 
32. cerebellar ataxia Cerebellar Ataxia/ Cerebellar ataxia/ (MH "Cerebellar Ataxia")  TI cerebellar ataxia OR AB 
cerebellar ataxia cerebellar ataxia.tw. cerebellar ataxia.tw. TI cerebellar ataxia OR AB 
cerebellar ataxia 






Charcot Marie Tooth.tw. TI charcot marie tooth OR AB 
charcot marie tooth 
TI charcot marie tooth OR AB 
charcot marie tooth 






TI familial amyloid* 
polyneuropathy OR AB familial 
amyloid* polyneuropathy  
TI familial amyloid* 
polyneuropathy OR AB familial 
amyloid* polyneuropathy familial amyloid* 
polyneuropathy.tw. 






(MH "Amyloid Neuropathies, 
Familial") 
TI Familial amyloid* neuropathy 
OR AB Familial amyloid* 
neuropathy Familial amyloid* 
neuropathy.tw. 
TI Familial amyloid* neuropathy 
OR AB Familial amyloid* 
neuropathy 
36. Familial Amyloidosis  Familial Amyloidosis.tw. Familial Amyloidosis.tw. (MH "Amyloidosis, Familial")  TI familial amyloidosis OR AB 
Familial amyloidosis  TI familial amyloidosis OR AB 
familial amyloidosis 






TI Familial Transthyretin 
Amyloidosis OR AB Familial 
Transthyretin Amyloidosis 
TI Familial Transthyretin 
Amyloidosis OR AB Familial 
Transthyretin Amyloidosis 
38. hereditary motor sensory 
neuropathy 
"Hereditary Sensory and Motor 
Neuropathy"/ 
Hereditary motor sensory 
neuropathy/ 
(MH "Neuropathies, Hereditary 
Motor and Sensory") 
TI hereditary motor sensory 
neuropathy OR AB hereditary 
motor sensory neuropathy hereditary motor sensory 
neuropathy.tw. 
hereditary motor sensory 
neuropathy.tw. 
TI hereditary motor sensory 
neuropathy OR AB hereditary 
motor sensory neuropathy 
39. degenerative disease degenerative disease.tw. Degenerative disease/ TI degenerative disease OR AB 
degenerative disease 
TI degenerative disease OR AB 
degenerative disease degenerative disease.tw. 
40. neurodegenerative 
disease 






neurodegenerative disease.tw. TI neurodegenerative disease OR 
AB neurodegenerative disease 
TI neurodegenerative disease OR 
AB neurodegenerative disease 
41. 1 or 2 or 3 
42. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 
34 or 35 or 36 or 37 or 38 or 39 or 40 
43. 41 and 42 
44. Limit 43 to 2009-present 
*Note: MESH headings and DE subjects used where available. Search limited to text word (.tw) and ‘all subheadings included’ in Medline and Embase. Search limited to 
title or abstract in CINAHL and PsycINFO. 
 









Study type Testing type  Main findings 







(Total score/ total 
possible score) 
and quality issues 
 Genetic counseling practice sourced from clinical experience 
1 Eno et al. 
(2020) e31 
USA 
HD Report the use of the 
electronic health record 
(EHR) for 
presymptomatic HD GT 
across different HD 
Centers (i.e. how the HD 
gene analysis is ordered, 
resulted and stored) 








Predictive Most teams have 
developed their own 
practices and there 
was much variation in 
whether the following 
were recorded in the 
EHR: encounters, 
notes, results, GT 
ordered, and whether 
pathology received by 
laboratory 
Education 0.93 (13/14) 
Question/objective 
not clearly described 
2 Bardakjian 
et al. (2019) 
e29 
USA 
HD Report the experience of 
a new HD Center since 
its inception, estimating 
the capture of the 
population served, 
describing the care 
provided and measuring 
changes in client 
behavior in response to 
release of research-
related information  
266 unique HD 
clients seen in HD 
Center 
145 seen in 2018: 
88 with manifest 
HD, 28 premanifest 
mutation carriers, 12 
who underwent 
predictive GT and 
did not carry an 
expanded allele, 8 
who requested but 
did not complete 
predictive GT, 7 who 
decided against 









demand for in-clinic 
multidisciplinary care 
Neurologist and nurse 
involved in 100% of 
encounters, followed 
by psychiatrist and 
genetic counselor 










0.92 (11/12)  
Results not 
sufficiently described 
3 Bonnard et 
al. (2019) e30 
France 
HD Compare the age, 
motivations, and time 
required before deciding 
to have GT performed 
between 25% at-risk and 
50% at-risk individuals 
Compare outcomes in 
25% at-risk individuals, 





1456 at 50% risk: 
73% underwent 
predictive GT 
155 at 25% risk: 









Predictive Most common 
motivation in 50% risk 
and 25% risk group 
was “to know” 
Four adverse 
reactions when 
individual at 25% risk 










design, and data 
collection not clearly 
described 
variant positive or variant 
negative 
Observe whether 
revealing the parent’s 
status adversely affected 
the parent–child 
relationship 
Understand the familial 
context that led them to 
request GT before their 
at-risk parent 
14/94 were variant 
positive 
9 variant positive 
individuals at 25% 
risk and 9 age-
matched variant 
negative individuals.  
 
 
relative: 3 intervening 
relatives became 
depressed, 1 suicide 1 
month after the result 
had been disclosed 
Theoretical 
framework/ wider 




reflexivity of the 
account not 
described 
Conclusions not well 
supported 
 
   Four participated in 
further semi-
structured interview 





4 Crook et al. 
(2019) e55 
Australia 
ALS Present the case of an 
ALS patient who 
underwent GT through 
our motor neurone 
disease clinic 
Highlight current 
limitations to analysing 
and interpreting C9orf72 
expansion GT results and 
describe how this 
resulted in discordant 
reports of pathogenicity 
between GT laboratories 
that confounded the GC 
process 

















and legal risks for the 




0.90 (9/10)  
Question/ objective 
not clearly described 
5 Klepek et al. 
(2019) e53 
USA 
ALS Characterize clinician 
practices regarding GT 
and GC, perceived 
challenges, and attitudes 
and other factors that 
may be associated with 
the offer of ALS GT 
Compare clinician 
attitudes towards GT to 
attitudes of persons with 
ALS 
80 ALS clinicians 











Diagnostic Lack of consensus in 
ALS GT practices: 
92.3% offered GT to 
patients with familial 
ALS, 57% to sporadic 
ALS with family history 
of dementia, 36.9% to 
sporadic ALS 
Divergent views 
between clinicians and 
patients: clinicians 
less likely to have GT 
themselves, or see 





6 Paneque et 
al. (2019) e36 
LONDs 
including: 
To describe the profile of 
the population seeking 
1498 requested 
predictive GT, 240 
Retrospective 
cohort study 
Predictive 45% did not follow up 













while also reflecting on 
the experience and 
conducting the protocol of 
multidisciplinary sessions 
since 1996 
withdrew, 28 were 
excluded 
1230 underwent 
predictive GT, 680 
non-carriers, 550 
carriers 
results, 29.6% were 
seen a year post-GT 
Most common reason 
for GT to reduce 
uncertainty (41.7%) 
Support  




HD Describe four cases in 
which the couples and 
clinicians involved were 
confronted with an 
unexpected outcome of 
prenatal GT 
4 couples in which 
expanded CAG 
repeats were 
observed in (or 








Population risks of HD 
should be a required 
discussion to ensure 
comprehensively 
informed reproductive 





et al. (2018) 
e58 
Ireland 
>6 LONDs Perform a retrospective 
chart review/ cohort 
analysis of the 
Neurogenetics clinic over 
12 months, reviewing 
symptoms and work up 
data 
27 individuals who 





Diagnostic Benefits of 
multidisciplinary team 











0.80 (8/10)  
Question/ objective 
not clearly described 
Conclusions not well 
supported 
9 Charles et 
al. (2017) e23 
USA 
HD Highlight the difficulties 
involved with care of an 
extended family with HD 
living on a small island 
nation due to their low 
socioeconomic status, 
barriers to accessing 
medical care and 
geographical isolation  
1 family with HD 
who live on several 
resource-limited 
Caribbean Islands 
Case study Diagnostic 
Predictive 
Genetic and clinical 
diagnosis can be 
impeded by lack of 
resources and lack of 













10 Goldman et 




Demonstrate the complex 
nature of GC and GT in 
the presence of 
psychiatric symptoms, 
whether emanating from 
the disease itself or the 








Predictive Psychiatric symptoms 
may emanate from the 
disease itself, or living 
in an affected family  
Health providers must 






results of living in an 
affected family 
positive and negative 
results 
Protocol may need to 
proceed slowly to 
foster positive 
outcome 
11 Mandich et 
al. (2017) e34 
Italy 
HD Report the 
sociodemographic 
characteristics of 
predictive GT applicants, 
their motivations and 
expectations, and the 
outcomes of the GC 
protocol during two 
decades of direct HD GT. 






Predictive Protocols completed 
more in men (68.5% 
vs 53.5%), those over 
25 (63.4% vs 48.1%) 
Factors influencing the 
decision-making 
process differed 






results and likely 
confounders not 
sufficiently described 
12 Mantero et 





Discuss the issues that 
arose in family GC for 
likely sporadic ALS and 
parkinsonism-dementia 
complex (ALS-PDC) 
1 individual with 
likely sporadic ALS-
PDC 
Case study Diagnostic GC important for 
family even if low 
recurrence risk, to 






13 Vajda et al. 
(2017) e52 
Ireland/ UK 
ALS Determine the degree of 
consensus among 
clinicians on the clinical 
use of GT in ALS and the 
factors that determine 
decision-making 
167 ALS clinicians 









90.2% offer GT to 
patients defined as 
having familial ALS, 
49.4% to sporadic 
ALS 





specialists and based 
on number of new 
patients seen 
Interpretation 1.00 (16/16) 
14 Clift et al. 
(2016) e65 
USA 
Prion disease Present an example case 
which discusses the 
psychosocial issues 
encountered and the role 
of GC in presymptomatic 
GT for incurable 
neurodegenerative 
conditions  
1 individual who 
sought predictive 
GT after familial 
CJD was confirmed 







approach key to GC 
care for the family 
Clinicians should be 






0.90 (9/10)  
Question/ objective 
not clearly described 
 





Explore a complex case 
where the GT wish of one 
family member was in 
direct conflict to that of 
1 family at risk of an 
unspecified LOND: 
the client at 25% 
risk requested 
Case study Predictive 
Reproductive 
Approach described to 
balancing competing 





another, assess the 
potential benefits and 
harms from acceding to 
or denying such a 
request, and present an 
approach to balancing 
competing rights of 
individuals within families 
predictive GT, the 
intervening relative 
did not wish to know 
and would commit 
suicide if mutation 
positive 
Magnitude of risks for 
client and relatives 
should be considered 
and every effort made 
to limit adverse 
outcomes in GT 
process 
16 Clement et 
al. (2015) e22 
France 
HD Review the historical 
context of guidelines and 
good clinical practice, the 
experiences of our team 
covering more than 20 
years of predictive GT for 
HD in France, and the 
new French legislation, 
all factors that regulate 
presymptomatic GT 
1705 persons at risk 
of HD who 
requested GC 





Predictive 47% withdrew from 
predictive GT protocol 
demonstrating that 
request for GT does 
not imply client wants 
to know 
New legislation of 
health providers to 
disclose family 
medical information 
may impact on 
predictive GT uptake, 
due to concerns about 
confidentiality 












Conclusions not well 
supported 
17 Cruz-Marino 
et al. (2015) 
e43 
Cuba 
SCA2 Review the 13-year 
experience of the SCA2 
predictive GT program in 
Cuba, describing different 
ethical, psychosocial, and 
technical challenges that 
led to major changes in 
the predictive GT protocol 
1193 individuals 
who requested 
predictive GT within 






895 completed the 
protocol: 43.4% 
uptake of predictive 
GT, 23.9% uptake of 
reproductive GT 
(10/33 couples carried 
test-positive fetus to 
term) 













et al. (2013) 
e44 
Cuba 
SCA2 Review the 11-year 
experience of predictive 
GT for SCA2, including 
the pre-GT opinions 








Predictive 768 completed the 
protocol, predictive GT 








the protocol and the 
profile of at-risk 
individuals who 
underwent GT 
eliminated from the 
predictive GT protocol 




18 Mandich et 
al. (2015) e50 
Italy 
ALS Report several issues in 
GC for ALS 
 
2 siblings with ALS 






One sibling may have 
phenocopy 
Benefits highlighted 
around exploring the 
complexity and pitfalls 
of GT and GC, the 
unexpected 
consequences for 







19 Klitzman et 







Survey attitudes and 
practices to understand 
whether providers in 
neurology and psychiatry 
discuss PND and PGD 
with clients, and if so, 
how frequently, when, 









Reproductive 24.9% of neurologists, 
and 31.9% of 
psychiatrists had 
discussed PND 
95.3% didn’t feel 
comfortable 
discussing PGD 
Education 1.00 (18/18) 
20 Schuler-
Faccini et 
al. (2014) e45 
Brazil, 
Portugal 
SCA3 Present our experience 
from two programs 
conducting predictive GT 
for SCA3 in Porto, 
Portugal and Porto 
Alegre, Brazil from 1999-
2012 
329 individuals who 
sought predictive 
GT for SCA3, 263 




















   Report an illustrative GC 
case 
1 family case 
example 
Case study    





Describe the challenges 
and lessons learned from 
a case in which an 
individual with a fatal 
condition was at risk for a 
second fatal condition 
and had difficulties with 
communication 
1 individual with 
ALS at 50% risk of 
HD 
Case study Diagnostic 
Predictive  
GC challenges 
inherent in this case: 
difficulty 
communicating due to 
disease progression, 
diagnostic 










22 Tanaka et 
al. (2013) e59 
Japan 
>6 LONDs Present the results of a 
follow-up nationwide 
survey on predictive GT 
for LONDs in Japan 
60 institutional 
members of Japan’s 
National Liaison 
Council for Clinical 







Predictive 301 clients interested 
in predictive GT over 5 
year period, 93 
underwent GT 
Lack of non-MD 








23 Gonzalez et 
al. (2012) e47 
Portugal 
SCA3 Assess the following in 
individuals who had 5 
years prior received 
positive results from 
predictive GT for SCA3: 
the psychological well-
being, family satisfaction/ 
occurrence of familial 
changes, and the role 
played by a number of 
factors, such as presence 
of symptoms, in general 
psychological wellbeing 
and family satisfaction 




predictive GT results 
approximately 5 
years prior and 











Predictive More than half 
demonstrated 
moderate (28.9%) or 
severe (23.7%) stress 
Most (59.6%) had high 
familial satisfaction 







Conclusions not well 
supported 
24 Reyes et al. 
(2012) e67 
France 
CADASIL Analyse the profiles and 
motivations of individuals 
at risk of CADASIL who 
requested predictive GT 
between 2003-2010 









Predictive 63% dropped out pre-
GT 
High overall quality of 
life reported in those 










   Identify the neurological, 
cognitive and 
psychological 
modifications observed in 
applicants who received 
a positive result 
11 completed neuro 
and psychological 
examination after 
receiving results and 
18 months later 
Prospective 
cohort 
   
25 Van Rij et 





HD Provide a comparative 
overview of PGD 
approaches and technical 
workup for HD between 







Reproductive  68% requested direct 
PGD GT, 32% 
requested exclusion 
PGD  
257 started PGD 




Study differences in the 
populations who apply for 
PGD and their 
reproductive histories 
Compare PGD results 
between the centers and 
compare them with 
literature data 
rejected, 61 refrained 
from PGD 
Overall delivery rate of 
couples starting >1 




al. (2012) e68 
Israel 
FSHD Present our experience of 
GT and GC for FSHD 
between 2000 -2006 
 
 
66 individuals who 
underwent GT for 
FSHD (59 









< 60% received pre-
GT GC, <30% 
received post-GT GC  
Pre-GT GC and 
multidisciplinary care 
emphasized due to 
complexities of 






  Present a case study 
which highlights a unique 
example of GC for 
dominant, relatively late-
onset disease 
1 family case 
example 
Case study    
27 Dufrasne et 
al. (2011) e21 
Canada 
HD Report and analyse the 
uptake, reasons given for 
requesting predictive GT, 
social and demographic 
characteristics, GT 
outcomes, and emotional 
reactions of individuals 
who proceeded with HD 
predictive GT and explore 
how best to fulfill 
participants' perceived 
needs 
181 individuals who 
requested predictive 







135 completed GT 
>1 reason for 














28 Cruz Marino 






Describe some of the 
ethical dilemmas that 
arose in predictive GT for 
hereditary ataxias in 
Cuba 
Explore the GC process 
and the decisions made 
during predictive GT and 
prenatal diagnosis 
4 case examples 
with ethical 
dilemmas: identical 
twins, GT an 
individual at 12.5% 
risk, GT a foetus at 









predictive GT are 
apparent and 
expanded guidelines 
required to address 






29 Butler et al. 
(2011) e62 
Canada 
AD Identify GC challenges 
and describe our specific 
GC approach for 
members of a 
geographically remote 
1 family with early-
onset familial 
Alzheimer disease 
(EOFAD) caused by 















0.80 (8/10)  
Question/ objective 
and study design not 
clearly described 






30 Futter et al. 
(2009) e18 
South Africa 
HD Compile a 
comprehensive profile of 
the participants who had 
undergone predictive GT 
for HD in the West Cape 
region of South Africa to 
inform changes to 
improve GC services 









Predictive Uptake of GT in those 
with mixed ancestry 
was significantly lower 
Possible barriers: 
limited access to GT 
due to low income or 
education 




and results not 
sufficiently described 
 










FTD Unclear. Assumed 
objectives:  
To report predictive GT 
uptake and outcomes 
between 1999-2008 
100-180 individuals 
from familial FTD 






Predictive 13 requested GC 
between 1999 and 
2002, 13 underwent 
GC between 2003 and 
2008 , 1 underwent 
PND 
Low acceptance of GT 







0.50 (5/10)  
Question/ objective 
and results not 
sufficiently described 
Study design not 
described 
Conclusions not well 
supported 
 
   To present a case study 
and propose the idea of 
separation-individuation 
 Case study   
 Genetic counseling practice trialed in clinical setting 
32 Spiers et al. 
(2020) e39 
UK 
HD Evaluate participants’ 
experience with a GC 
narrative group session 
to determine whether 
participating in a single 
GC narrative group is 
perceived as helpful 
12 individuals who 
had tested positive 
on predictive GT 
and had participated 
in one of three GC 
group sessions 
between December 
2017 and March 
2018 
Qualitative Predictive Group had a positive 
impact of being able to 
meet and empathize 
with others in a similar 
situation, increased 
disclosure to others 
and improved mood 
and future outlook 
Support 1.00 (20/20) 
 Stopford et 
al. (2020) e40 
UK 
HD Explore presymptomatic 
individuals’ (and their 
partners) experiences of 
a structured narrative 
group session to 
understand the value and 
feasibility of integrating 
narrative practices within 
a GC session 
8 individuals who 
were purposively 
selected and 
attended a single 
narrative group 
sessions, 6 mutation 
positive, 2 male 
partners (not at risk 
of HD) 
Qualitative Predictive Positive feedback 
received, highlighting 
importance of time 
and space for 
structured sharing of 
experiences 
Support 1.00 (20/20) 
 Macleod et 
al. (2018) e38 
UK 
HD Explore the feasibility of 
offering narrative group 
sessions in the context of 
a predictive GT follow-up 
clinic  
9 individuals who 
had tested negative 





Predictive Group sessions were 
seen as safe and 
enjoyable, and 
benefits included 
feeling less isolated, 
Support 0.95 (38/40) 
Qualitative: analytic 
methods and 
reflexivity of the 
 being inspired by 
other’s stories and 
connecting as a group 
account not clearly 
described 
 
   Determine how 
participants experienced 
the session and whether 
they would recommend 
participation to others 
 Qualitative   







Develop a brief, reliable 
and valid instrument to 
screen psychosocial risk 
among those who are 
undergoing GT for adult-
onset hereditary diseases 
31 individuals from 
HD families 
undergoing GT 
participated (4% of 
total participants)  
Prospective 
cohort 
Unspecified 5 (23.8%) 
demonstrated distress 
1 month post-GT 
Screening tool 
developed for further 







34 Hawkins et 
al. (2013) e15 
Canada 
HD Report the predictive GT 
undertaken between 
January 2011- January 




access to HD predictive 
GT while maintaining 




predictive GT, 28 
requested telehealth 
(15 attended at least 
one session, 14 
completed survey, 
10 received results, 
8 completed 2nd 
survey) 13 who 
utilized usual care 
(11 received results 




Predictive No significant 
differences between 
individuals undergoing 
GT in person or by 
telehealth with respect 




Majority were satisfied 











35 Mariotti et 







Define a well-framed, 
structured and easy 
procedure for GC in 
subjects at risk for 
LONDs, in which 
psychological support is 
intended both for the 
client and the health 
provider 
Verify feasibility and 
effectiveness of this 
procedure and compare 
possible differences in 
the impact of predictive 




predictive GT GC 
60 at risk of HD, 32 
at risk for SCAs  
Consecutive 
case series 
Predictive 72 (78%) proceeded 
with program, 55 
(60%) received GT 
result, 38 (41%) 
completed entire 
program 
The need for 
psychological support 
was recognized for 5 
mutation carriers and 
a non-carrier 
Clinical conference 







 Genetic counseling practice recommended from clinical research 
36 Oosterloo et 
al. (2020) e35 
The 
Netherlands 
HD Provide an overview of 
the experiences of Dutch 
persons at risk of HD in 
consulting a neurologist 
before or after DNA 
analysis 
Make a recommendation 
if and at what moment in 
the GT procedure the 
judgment of a neurologist 
is desirable 
71 individuals at risk 
of HD who visited 
one of 4 Dutch GC 
clinics, 32 saw a 
neurologist before 
GT, 12 after GT, 27 








Predictive 41/44 felt visit to 
neurologist was 
positive 
59 desired consulting 
a neurologist, even 
those who did not 
have the gene 
expansion, suggesting 
consultation before GT 







37 Schwartz et 
al. (2019) e66 
France 
Prion disease Understand the feelings 
of at risk individuals 
towards predictive GT, 
their decision-making, 
and the long-term 
consequences 
 








carriers and 6/10 












of living in a family 






Case series and 
qualitative study: 
question/ objective 
















   Understand specific 














predictive GT to identify 
variables that may predict 
middle and long-term 
psychological disturbance 
due to predictive GT 






167 at risk of TTR-






can inform those who 
may need 
psychological support 
several years later 
Result of predictive 





39 Stuttgen et 
al. (2018) e1 
USA 
HD Analyse long term 
changes in risk 
perception, and 
investigate factors that 
contributed to changes in 
risk perception 
186 individuals who 
underwent 
predictive GT and 
had provided risk 
perception values 







Predictive 27% had unexpected 
changes in risk 
perception after GT 
results disclosure, 




influenced by more 








not clearly described 
Theoretical 
framework and 




    39 had concurrent 
research clinic notes 
and semi-structured 
interviews, 27 
referred to risk 
perception in 
interviews 
Qualitative   
 Stuttgen et 
al. (2018) e2 
USA 
HD Examine opinions on the 
importance of autonomy 
in the decision to be 
tested for HD, whether a 
formal HD GT protocol is 
necessary, whether a 
physician ordering HD 
GT in the absence of a 
formal HD protocol is 
acceptable, whether 
ordering presymptomatic 
GT for HD online via a 
direct-to-consumer (DTC) 
website is acceptable, 
and whether incidental/ 
secondary findings of HD 
should be returned in the 
context of whole exome/ 
genome sequencing 
39 recent interviews 
with individuals who 
underwent 
predictive GT 
between 1986-1998  
15 expansion 
carriers, 21 non-
carriers, 3 who 
dropped out before 
GT result disclosure 
Qualitative 
 
Predictive Most supported 
individual’s right to 
decide whether and 
when to pursue HD 
GT (31/38), use of a 
formal HD GT protocol 




Most were opposed to 
physician ordering 
(28/35) and DTC HD 
GT (24/31) in the 
absence of a formal 
protocol and returning 
a secondary finding of 
an expanded HD allele 
(18/37) 
Counseling 0.75 (15/20) 
Question/ Objective 
not clearly described 
Theoretical 
framework and 
reflexivity of the 
account not 
described 
40 Ibisler et al. 
(2017) e14 
Germany 
HD Prospectively follow the 
decision-making process 
of individuals at risk in 
our center  
72 individuals who 
participated in at 






Predictive 93.4% had already 
sought information via 
the internet before the 
first GC session 
More participants with 
an affected mother 
(56.9%) than an 





0.86 (36/42)  
Theoretical 
framework/ wider 




Data analysis and 
reflexivity of the 
account not clearly 
described 
 
   Explore their experiences 
following the decision as 
well as the impacts of GT 
results 
31 participated in 
telephone interview 
Qualitative   









Understand why subjects 
at-risk of LONDs want to 
undergo predictive GT 
Compare results with the 
motivations of subjects 
at-risk for hereditary 
haemochromatosis  
213 individuals at 
risk of 3 LONDS 
(174 TTR-FAP, 34 
HD, 5 SCA3) 
Qualitative 
 
Predictive Most common 
motivations: reasons 
related to the future, 
reasons related to 
others and curiosity 
and the need to know 
- all reasons external 
and unrelated to the 








reflexivity of the 
account not clearly 
described 
 















Investigate what subjects 
at risk for TTR-FAP, HD, 
and SCA3 know about 
these 3 diseases in 
comparison with the 
knowledge that subjects 
at risk for HH have about 
the conditions 
213 individuals at 
risk of 3 LONDS 
(174 TTR-FAP, 34 
HD, 5 SCA3) 
Qualitative Predictive References to the 
disease, references to 
the family and 
metaphors were 
mentioned more by 
subjects at risk of a 
LOND 
Education 0.90 (18/20) 
Analytic methods 
and reflexivity of the 
account not clearly 
described 
42 Quaid et al. 
(2017) e6 
USA 
HD Examine factors 
associated with the 
decision of research 
participants who changed 
their minds and opted to 
undergo presymptomatic 
HD GT, compared with 
those who still chose not 
to be tested 
1001 individuals at 
risk of HD who are a 
part of the PHAROS 
observational study, 
104 underwent 




Predictive Baseline behavioral 
scores (especially 
apathy) were more 
strongly associated 
with later GT than 
motor and chorea 
scores 
Following GT, 56% of 
those who tested 
negative had less 
depression compared 
to prior, depression 
stayed the same or 
increased for 64% of 






et al. (2016) 
e25 
Sweden 
HD Describe a couple’s long-
term experiences (from 6 
months after result 
disclosure) and the 
consequences of 
predictive GT 
1 couple interviewed 
separately on 9 







consequences of GT 
devastating for both 




difficulties and divorce 
Long-term support 
recommended for both 





et al. (2013) 
e24 
Sweden 
HD Describe the prospective 
experience of a client 
undergoing a 
presymptomatic GT for 
HD, and her husband in 
order to obtain an 
understanding of the 
client’s perspective and 
the effect on the couple 
1 couple interviewed 
separately on 9 






Predictive Throughout pre- and 
post-GT, need to 
acknowledge needs of 
client and partner, 
particularly important 







44 Benatar et 
al. (2016) e49 
USA 
ALS Highlight clinically 
relevant aspects of the 
genetic complexity of 
ALS and present an 
approach to predictive 
GT that we have 
developed and refined 
over the last 8 years in 
the pre-FALS study 
317 GC sessions 
with 161 individuals 
at 50% risk of 
familial ALS who are 
part of the pre-fALS 
study 
75 post-GT sessions 
with 63 individuals 




Predictive Clients may be 
interested in research 
participation without 
results being disclosed 










0.70 (7/10)  
Study design and 
results not 
sufficiently described 
Conclusions not well 
supported 
 Fanos et al. 
(2011) e48 
USA 
ALS Explore the basis for 
participants’ decision to 
learn results of 
presymptomatic GT or 
not, understand the 
psychosocial impact of 
the decision and assess 
attitudes toward receiving 
results by telephone or in 
person 
20 individuals at 
50% risk of familial 
ALS, who are part of 
the pre-fALS study 
14 elected to 
receive results (8 
mutation carriers, 6 
non-carriers) 
Qualitative Predictive Telephone counseling 
as option for those 
who can’t easily 
access in person 
counseling 
Those who decline GT 
may change their mind 
in future 





0.80 (16/20)  
Theoretical 
framework and 
reflexivity of the 
account not 
described 
45 Paneque et 
al. (2015) e57 
Portugal 
All LONDs 
tested for in 
Portugal 
Explore professionals’ 
views of relevant quality 
indicators in their own GC 
practice concerning 
predictive GT for LONDs 
Examine current 
assessment of such GC 
practice in Portuguese 
genetic services 
18 genetic health 
professionals (85% 
of total eligible 
interviewees) 
Qualitative Predictive Core components of 
GC identified 
Challenges specific to 
LONDs: ambiguity of 
health/ illness status, 
time burden for health 
professionals 
Health professionals 
associated quality with 
non-directiveness, 
information given and 
comprehension pre-
GT, decision-making 







0.90 (18/20)  










From the client’s 
perspective, recognize 
aspects relevant across 
the predictive GT and GC 
process that might 
indicate an effective 
practice 
Analyse aspects of 
current protocols that 





13 for TTR-FAP, 6 
for HD, 3 for SCA3 
Qualitative 
 
Predictive Highlight the need of 
health providers to be 
armed with personal 
and professional skills 










0.90 (18/20)  
Data analysis and 
reflexivity of the 
account not clearly 
described 





Compare the behavior 
symptoms inventory (BSI) 
psychopathological 
indices observed before 
and one year after 





depending on type of risk 
disease, carrier or non-
carrier status and 
demographic variables 
(age, gender, marital 
status) included in the 
general protocol. 
53 individuals who 
underwent 
predictive GT (40 for 
TTR-FAP and 13 for 






Predictive BSI levels across the 
time points were 
higher in both those 
who tested negative 
and positive, 
compared to controls 
Average BSI levels 
decreased post-GT 
regardless of the 




48 Uhrova et 
al. (2013) e5 
Czech 
Republic 
HD Characterize the 
differences in psychiatric 
examination and 
psychometric measures 
between people at risk 
who were recommended 
to postpone predictive 
GT, and those who 
proceeded 
52 individuals who 
underwent 
psychiatric 
examination as part 
of the HD predictive 
GT protocol: 41 
continued with GT 
(19 tested positive, 










whether to consider 
postponing GT than 
formalized psychiatric 
screening tools 
Motivations must be 
assessed pre-GT, 
postponing may be 






49 Van Rij et 
al. (2013) e7 
The 
Netherlands 
HD Create a better 
understanding of the 
motives and experiences 
of couples opting for 
exclusion PND or PGD 




Qualitative Reproductive 7 couples had 
terminated 11 
pregnancies, none 
showed regret. Some 





Reflexivity of the 
account not clearly 
described 
Study the acceptability of 
exclusion PGD among 
candidates 
13 PND with 
exclusion  
6 PGD with 
exclusion (2 couples 
experienced both) 





before, during and 
after PND/PGD 
50 Rodrigues 










Describe the Brazilian 
public health system 
experience of a predictive 
GT program, run in 
accordance with the 
international guidelines 
for HD, SCAs and TTR-
FAP between 1999-2009 
183 individuals who 
commenced 
predictive GT (147 
at risk for SCA3, 22 
for HD, 8 for TTR-























  Conduct a subsequent 
survey of the 
psychological 
characteristics of 
individuals who sought 
predictive GT, to detect 
differences between 
groups 
31 participated in a 
follow-up interview 










   
51 Alexander 
et al. (2011) 
e63 
Canada 
AD Assess the effectiveness, 
outcomes and costs of 
requesting medical 
records for the 
confirmation of client–
reported family histories 
of dementia 
275 medical record 
requests during the 
24-month period of 
January 1, 2005–
December 31, 2006 
Consecutive 
case series 
Diagnostic Useful medical 
records obtained from 
92 (33.5%) requests: 




history was accurate 
in 84% 
Almost 500 hours of 
GC time spent 
Interpretation 0.75 (15/20)  
Question/ objective, 





 Genetic counseling practice recommended from non-clinical research 
52 Cahn et al. 
(2020) e46 
USA 
SCA1, 2, 3, 6, 
7, 8, 14, 17, 35 
Assess knowledge of 
genetic risk and 
perceptions of 
reproductive options in 
individuals with a 
diagnosis of 
spinocerebellar ataxia 
94 individuals with 





Reproductive  39.8% would consider 
PGD, less PND 
(number unclear) 
79.8% would not 
consider donated 
embryos, 63-74% 







factors: child will not 
inherit SCA, cost and 
risk to mother or child 
53 Withers et 





Examine cultural beliefs 
about Alzheimer’s 
disease and genetic 
screening among at risk 
populations of Mexican 
heritage 
123 individuals from 
families living in 
Mexico and 
California in which 
Alzheimer’s disease 
mutations were 






Predictive Few respondents 
understood their risk 
of inheriting a 
pathogenic variant 
causing Alzheimer’s 
disease in their family 
Family myths and 
stigma also present in 
the family 
Education 0.87 (33/38) 





body of knowledge 
not clearly described 












HD Explore the intersections 
between genes, the body 
and the lived experience 
of a genetic disease to 
contribute to a deeper 
understanding of the lived 
experience of genetic 
diseases 
11 individuals from 
HD families  
2 affected, 1 
presymptomatic 
carrier, 2 tested 
negative, 1 untested 




Lived experience is 
fluid and dynamic and 
must be addressed as 
part of GC process 




Reflexivity of the 
account not clearly 
described 
55 Hartzfeld et 
al. (2015) e54 
USA 
ALS Learn how familial ALS 
influences reproductive 
decisions, the potential 
influence of others, 
factors considered during 
the decision-making 




10 individuals from 
familial ALS families 
who were aware of 
the risk of the 
disease when they 
had children 
Qualitative Reproductive Those who decided to 
have children always 
planned on having 
children, hoped for a 
cure and compared 
ALS favourably to 
other diseases 
Those who chose not 
to have children had 
extensive experience 
of ALS and caretaking, 
saw ALS as inevitable 




0.80 (16/20)  
Theoretical 
framework/ wider 
body of knowledge 
not clearly described  





56 Paneque et 
al. (2015) e61 
Portugal 
LONDs Identify quality aspects of 
effective GC practice in 
presymptomatic GT for 
45 experts with 
extensive 
experience of GC 
from 11 countries, 
29 completed round 












1 (64.4%), 13 
completed round 2 
(31.1%) and 17 
competed round 3 
(37.7%) 
practice; and protocol 
standards were 
developed 
Most relevant quality 
indicators were related 
to consultand-
centered practice, and 
advanced counseling/ 
interpersonal skills 
57 Hawkins et 
al. (2013) e28 
Canada 
HD Understand the obstacles 
to GT in terms of 
accessibility of services in 
Vancouver, as well as 
exploring the 
mechanisms by which 
this issue may be 
addressed 
33 participants 
recruited based on a 
non-probability 
sample 
24 tested, 9 rural, 15 
non-rural 
9 not tested, 3 rural, 
6 non-rural 
Qualitative Predictive Barriers to 
accessibility of GT: 
distance (time and 
travel, financial and 
opportunity costs, 
stress of travel) and 






 0.75 (15/20) 
Theoretical 
framework/ wider 
body of knowledge, 
data analysis and 
reflexivity of the 






Virani et al. 
(2013) e41 
Canada 
HD Develop a patient-
friendly, comprehensive, 
accessible Web-based 
tool to provide accurate 
information about 
predictive GT for HD 
Pilot the content and test 
usability of the website, 
and modify the website  
33 individuals from 
HD families, 9 had 
not had predictive 
GT, 24 had with 17 







Predictive Effective website 
included unbiased 
overview of important 






















body of knowledge 
and reflexivity of the 
account not clearly 
described 
 
   10 individuals who 
had participated in 
above study, 5 
genetic counselors 
across North 
America, 10 HD 
researchers and 














HD Explore the healthcare 
experiences of families 
affected by HD, and elicit 
their suggestions for 
improvement in the 
24 individuals from 
HD families 
2 affected, 3 
presymptomatic 












Reflexivity of the 
account not clearly 
described 
quality of care provided to 
them. 
negative, 2 tested - 
intermediate result, 
2 tested – results 
not received, 6 
untested and at risk, 
4 spouses 
frustrated by lack of 
knowledge of family 
physicians 
Regular follow-up and 











Investigate the range of 
possible 
misunderstandings 
related to genetics that 
clients may have, the 
reasons why these may 
persist, and the 
implications that these 
may have. 
21 individuals with 
or at risk of HD, 15 
asymptomatic, 6 
symptomatic, 14 
had undergone GT, 
10 were positive, 10 







about GT: that they 
could control disease 
onset, beliefs about 
inheriting mutations 
and physical traits 
together or that more 
biological material was 





Reflexivity of the 





HD Explore the unique issues 
surrounding being 
diagnosed with a chronic, 
progressive, genetic 




diagnosed with HD 
within the past year 
Qualitative Diagnostic 
Predictive  
Lived experience of 
HD had the following 
key chapters in the 
narrative: discovering 
the existence of HD, 
confirming the 
diagnosis, revealing 
the diagnosis to 
others, and 
experiencing the 






Reflexivity of the 
account not clearly 
described 
#Conditions not of interest in brackets; *Only population of interest included 
KEY: AD: Alzheimer’s disease, ALS= amyotrophic lateral sclerosis, CADASIL= cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, FSHD= 
Facioscapulohumeral muscular dystrophy, FTD= frontotemporal dementia, GC= genetic counseling, GT= genetic testing, HD= Huntington’s disease, PGD= preimplantation genetic diagnosis with 
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